Pancreatic Cancer Research

ResearcherNagasaki UniversityActive in the last 2 years

Susumu Eguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7876-0152; OpenAlex author ID A5032856038, A5114020914. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 13

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Co-author DOI 10.1002/ags3.70090↗
  2. Feasibility of serial cfDNA measurement after perflubutane microbubble (Sonazoid®) administration in patients with pancreatic ductal adenocarcinoma: a first-in… Last author DOI 10.1186/s13104-026-07869-5↗
  3. Stress exacerbates pancreatic cancer both directly and indirectly by creating an immunosuppressive environment. Last author DOI 10.1002/jhbp.1295↗
  4. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  5. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.15802↗
  6. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Mult… Co-author DOI 10.29337/ijsp.142↗
  7. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Res… Co-author DOI 10.21873/anticanres.14593↗
  8. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  9. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0210178↗
  10. No-touch isolation techniques for pancreatic cancer. First author DOI 10.1007/s00595-016-1317-5↗
  11. Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00535-014-1030-3↗
  12. Laparoscopic distal pancreatosplenectomy for pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00595-014-1021-2↗
  13. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. Last author DOI 10.1097/mpa.0b013e318269d281↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hajime Matsushima · 4 shared papers, 2015–2026 · strength 0.60
  2. Hirokazu Noshirο · 4 shared papers, 2019–2026 · strength 0.57
  3. Hajime Imamura · 3 shared papers, 2022–2026 · strength 0.55
  4. Tamotsu Kuroki · 5 shared papers, 2013–2022 · strength 0.46
  5. Toru Hisaka · 2 shared papers, 2023–2026 · strength 0.37
  6. Naoki Ikenaga · 2 shared papers, 2023–2026 · strength 0.37
  7. Kazuyoshi Nishihara · 3 shared papers, 2019–2023 · strength 0.34
  8. Masafumi Inomata · 3 shared papers, 2019–2023 · strength 0.34
  9. Yoshihiro Miyasaka · 3 shared papers, 2019–2023 · strength 0.34
  10. Takao Ohtsuka · 3 shared papers, 2019–2023 · strength 0.34
  11. Masaaki Hidaka · 2 shared papers, 2022–2023 · strength 0.30
  12. Masafumi Nakamura · 2 shared papers, 2019–2026 · strength 0.30
  13. Hiroaki Nagano · 2 shared papers, 2019–2026 · strength 0.30
  14. Hiroaki Nagano · 2 shared papers, 2021–2023 · strength 0.27
  15. Masafumi Nakamura · 2 shared papers, 2021–2023 · strength 0.27
  16. Yasuhisa Mori · 1 shared paper, 2026 · strength 0.23
  17. Teijiro Hirashita · 1 shared paper, 2026 · strength 0.23
  18. Hiromitsu Hayashi · 1 shared paper, 2026 · strength 0.23
  19. Tomoharu Yoshizumi · 1 shared paper, 2026 · strength 0.23
  20. Hiroto Matsui · 1 shared paper, 2026 · strength 0.23
  21. Shingo Kozono · 1 shared paper, 2026 · strength 0.23
  22. Hirohisa Okabe · 1 shared paper, 2026 · strength 0.23
  23. Hiroshi Kurahara · 2 shared papers, 2019–2023 · strength 0.22
  24. Hideo Baba · 2 shared papers, 2019–2023 · strength 0.22
  25. Takahiro Ikeda · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.